Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
MREO 
Mereo BioPharma Group PLC ADR (MREO)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: MREO (2-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Number of Analysts
8 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $7.02
1 Year Target Price $7.02
| 6 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 0.99% | Avg. Invested days 37 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/14/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 271.89M USD | Price to earnings Ratio - | 1Y Target Price 7.02 |
Price to earnings Ratio - | 1Y Target Price 7.02 | ||
Volume (30-day avg) 8 | Beta 0.42 | 52 Weeks Range 1.47 - 5.02 | Updated Date 08/15/2025 |
52 Weeks Range 1.47 - 5.02 | Updated Date 08/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.3 |
Earnings Date
Report Date 2025-08-12 | When - | Estimate -0.0243 | Actual -0.02 |
Profitability
Profit Margin - | Operating Margin (TTM) -1950.8% |
Management Effectiveness
Return on Assets (TTM) -35.13% | Return on Equity (TTM) -74.61% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 219546498 | Price to Sales(TTM) 543.78 |
Enterprise Value 219546498 | Price to Sales(TTM) 543.78 | ||
Enterprise Value to Revenue 439.09 | Enterprise Value to EBITDA -1.21 | Shares Outstanding 159000000 | Shares Floating 509030471 |
Shares Outstanding 159000000 | Shares Floating 509030471 | ||
Percent Insiders 0.96 | Percent Institutions 77.28 |
Upturn AI SWOT
Mereo BioPharma Group PLC ADR
Company Overview
History and Background
Mereo BioPharma Group PLC ADR was founded in 2015 as a biopharmaceutical company. It focuses on developing and commercializing innovative therapeutics for rare diseases. It went public through a reverse merger with OncoMed Pharmaceuticals in 2019.
Core Business Areas
- Oncology: Development of cancer therapies.
- Endocrinology: Development of treatments for endocrine disorders and rare bone conditions.
- Rare Diseases: Focus on therapies for rare and underserved medical conditions.
Leadership and Structure
Dr. Denise Scots-Knight is the CEO. The company has a board of directors and operates with a functional organizational structure, with departments dedicated to research, clinical development, and commercialization.
Top Products and Market Share
Key Offerings
- Setrusumab (UX143): A monoclonal antibody in Phase 3 development for Osteogenesis Imperfecta (OI) in patients aged 5 to <26 years old. No approved therapies target the underlying mechanism of OI. Competitors include bone-modifying agents like bisphosphonates.
- Alvelestat: A neutrophil elastase (NE) inhibitor in Phase 2 development for Alpha-1 Antitrypsin Deficiency-associated lung disease (AATD-LD). Competitors in AATD-LD include augmentation therapies and potential gene therapies.
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by high R&D costs, lengthy regulatory approval processes, and intense competition. Focus is increasing on rare diseases and personalized medicine.
Positioning
Mereo focuses on niche markets and orphan drug designations, offering potential for accelerated development and market exclusivity. It faces competition from larger pharmaceutical companies with greater resources.
Total Addressable Market (TAM)
The TAM for rare diseases is substantial, estimated to be in the billions of dollars. Mereo is positioned to capture a portion of this market with its pipeline of novel therapies. For Setrusumab in OI: conservative estimates is around $500M, positioning for a large portion dependent on clinical trial data and market penetration.
Upturn SWOT Analysis
Strengths
- Pipeline of novel therapeutics targeting rare diseases
- Orphan drug designations offering market exclusivity
- Experienced management team
Weaknesses
- Reliance on clinical trial success
- Limited financial resources compared to larger pharmaceutical companies
- High risk of drug development failure
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion of pipeline through acquisitions or in-licensing
- Potential for accelerated regulatory approval pathways
Threats
- Competition from other pharmaceutical companies
- Clinical trial failures
- Changes in regulatory environment
Competitors and Market Share
Key Competitors
- Ultragenyx Pharmaceutical Inc. (RARE)
- Ascendis Pharma A/S (ASND)
Competitive Landscape
Mereo's competitive advantage lies in its focus on rare diseases and novel therapeutics. However, it faces challenges from larger pharmaceutical companies with greater resources and established market presence.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been driven by clinical trial advancements and securing financing.
Future Projections: Future growth depends on successful clinical trial outcomes and commercialization of pipeline products. Analyst estimates vary widely, reflecting the inherent risks of drug development.
Recent Initiatives: Recent initiatives include advancing Setrusumab through Phase 3 trials, and advancing Alvelestat through Phase 2 trials.
Summary
Mereo BioPharma is a clinical-stage biopharmaceutical company with a focus on rare diseases. Its strengths are its novel pipeline and orphan drug designations, but it faces weaknesses due to limited resources and clinical trial risk. Key opportunities include partnerships and pipeline expansion. Threats include competition and trial failures; these factors result in a high-risk investment.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings (SEC)
- Analyst reports
- Company website
- ClinicalTrials.gov
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Investment decisions should be made based on individual circumstances and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Mereo BioPharma Group PLC ADR
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2019-04-24 | Co-Founder, CEO & Executive Director Dr. Denise Vera Scots-Knight Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 36 | Website https://www.mereobiopharma.com |
Full time employees 36 | Website https://www.mereobiopharma.com | ||
Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. It develops Etigilimab, an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for use in the treatment of tumors. The company is also developing Navicixizumab, which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod, a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole, an oral aromatase inhibitor, which is in Phase 2 trials for use in the treatment of hypogonadotropic hypogonadism. In addition, it develops rare disease product candidates, including Setrusumab, an antibody for the treatment of osteogenesis imperfecta; and Alvelestat, an oral small molecule that is in Phase II clinical trial to treat Alpha-1 anti-trypsin deficiency. The company has a license agreement with Feng Biosciences for the development and commercialization of navicixizumab; license agreement with ReproNovo for the development and commercialization of leflutrozole; and licensing agreement with AstraZeneca. Mereo BioPharma Group plc was incorporated in 2015 and is headquartered in London, United Kingdom.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.